Cambridge Investment Research Advisors, Inc. Kymera Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 9,014 shares of KYMR stock, worth $266,994. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,014
Previous 9,014
-0.0%
Holding current value
$266,994
Previous $427,000
14.99%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding KYMR
# of Institutions
187Shares Held
60.3MCall Options Held
49.6KPut Options Held
17K-
Price T Rowe Associates Inc Baltimore, MD6.87MShares$203 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$178 Million2.67% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$153 Million7.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.15MShares$153 Million3.02% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$145 Million32.49% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $1.62B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...